安徽医药AnhuiMedicalandPharmaceuticalJournal2023Jul，27（7）代谢组学在冠状动脉粥样硬化性心脏病中的研究进展王治财1，2，仓彦2作者单位：1安徽理工大学医学院，安徽淮南232000；2同济大学附属上海市第十人民医院心内科，上海200072通信作者：仓彦，男，副主任医师，研究方向为心血管病学，Email：cang_gu@aliyun.com摘要：冠状动脉粥样硬化性心脏病（简称冠心病）是最常见的临床心血管疾病，也是世界范围内诱导人死亡的最主要疾病。冠心病病人体液中代谢物浓度的变化反映了冠心病的发病和发展过程，也是心脏功能障碍的生物学特征，这促使人们利用代谢组学探索新的生物标志物来更好地阐明冠心病的机制。代谢组学在冠心病中的应用有助于冠心病的早期诊断，个体化治疗和预测其预后。该研究简要阐述了国内外冠心病代谢组学的研究现状，利用代谢组学为冠心病机制的进一步研究提供依据。关键词：冠状动脉粥样硬化性心脏病（冠心病）；代谢组学；生物标志物；肌酸激酶；脂蛋白类；气相色谱-质谱法ResearchprogressonmetabonomicsofcoronaryheartdiseaseWANGZhicai1,2,CANGYan2AuthorAffiliations:1SchoolofMedicine,AnhuiUniversityofScienceandTechnology,Huainan,Anhui232000,China;2DepartmentofCardiology,ShanghaiTenthPeople´sHospital,TongjiUniversitySchoolofMedicine,Shanghai200072,ChinaAbstract：Coronaryheartdisease(CHD)isthemostcommonclinicalcardiovasculardisease,anditisalsothemainseriousdiseaseinducinghumandeathallovertheworld.Thechangesofmetaboliteconcentrationsinbodyfluidsofpatientswithcoronaryheartdis‑easereflectthepathogenesisanddevelopmentofcoronaryheartdisease,andarealsothebiologicalcharacteristicsofcardiacdysfunc‑tion.Metabonomicsresearchcanfindnewbiomarkerstobetterclarifythemechanismofcoronaryheartdisease,whichishelpfultotheearlydiagnosis,individualizedtreatmentandprognosisofcoronaryheartdisease.Therefore,thestudyofmetabonomicsincoronaryheartdiseaseisofgreatsignificance,anditisalsoanewfieldinsystembiology.Thispaperbrieflydescribestheresearchstatusofmetabonomicsofcoronaryheartdiseaseathomeandabroad,inordertoprovidebasisforfurtherstudyofthemechanismofcoronaryheartdiseasebyusingmetabonomics.Keywords：Coronaryheartdisease;Metabolomics;Biomarker...
